about
Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomographyApplication of cross-species PET imaging to assess neurotransmitter release in brainDevelopment of new brain imaging agents based upon nocaine-modafinil hybrid monoamine transporter inhibitorsRadioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites--current status[11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomographyPositron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects11C-labelling of dimethylphenethylamine in two different positions and biodistribution studiesChanges in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primatesDevelopment of a small D-enantiomeric Alzheimer's amyloid-β binding peptide ligand for future in vivo imaging applicationsA PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brainConfirmation of fenfluramine effect on 5-HT(1B) receptor binding of [(11)C]AZ10419369 using an equilibrium approachJoint explorative analysis of neuroreceptor subsystems in the human brain: application to receptor-transporter correlation using PET data.Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data.Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907.Carbon-11 pb-12: an attempt to visualize the dopamine d(4) receptor in the primate brain with positron emission tomography.Error analysis for quantification of [(11)C]FLB 457 binding to extrastriatal D(2) dopamine receptors in the human brain.SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP.Synthesis of ([(11)C]carbonyl)raclopride and a comparison with ([(11)C]methyl)raclopride in a monkey PET study.Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease.D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model.N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrierDopamine beta-hydroxylase-deficient mice have normal densities of D(2) dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding.Radioligands for the study of brain 5-HT(1A) receptors in vivo--development of some new analogues of way.Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.Distribution of 5-HT4 receptors in the postmortem human brain--an autoradiographic study using [125I]SB 207710.The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ an[¹²⁵I]SD-7015 reveals fine modalities of CB₁ cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's diseaseDiscovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors.Brain radioligands--state of the art and new trends.Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands.PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man.Preclinical characterization of a novel class of 18F-labeled PET tracers for amyloid-β.PET studies with carbon-11 radioligands in neuropsychopharmacological drug development.Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.[11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET.Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PETThe PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain.PET and SPET tracers for mapping the cardiac nervous system.Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients.Evaluation of [11C]PipISB and [18F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type-1 receptors in vivo.
P50
Q24630426-3F59C5B5-4AAC-4D32-A764-21CEED5023F1Q26865012-7D3B5FD6-8143-481E-ADA3-54B6458F2F7CQ28235181-0AF254E4-32FB-485E-BDC9-EB1DFE603EDAQ28263464-00BF1EE7-E301-448C-BEFC-BCADF5A246B8Q28276154-D92993E1-9BBC-405C-8C2B-75AE3A1E1139Q28327576-2AAEC797-51DB-4E0D-BF56-698363F73C56Q28342978-A9627B81-5A4D-4F8D-A0EF-86E76F0C15B6Q28369835-198AC20B-6D78-44AD-903D-590DEEF7F345Q28728851-E2FC5F6C-1236-4F61-992B-6AA6D5C0D0C5Q29400289-4698A575-2772-4882-9938-8CE7B8EC9E42Q30512685-05ADB49E-54CD-4F8C-B3CE-3D69B85D63A9Q30940742-C5C8F917-F1FC-4D17-B076-0F217C1663EAQ31060934-0CE380F9-EF05-481D-AFE4-7A7F3E497B4AQ31485676-B04C9255-A9C1-4883-87FA-217D89D7DFD2Q31814202-FADAC673-30A6-4F8B-99DB-74809B99A35EQ31917746-5B9F0FC5-DDF1-4746-AA2B-F8E42D92C1DEQ32001995-A9AF33A7-95EE-4173-B05C-23BDD90536FCQ33465817-55FA90DE-3C0A-40F2-A13D-DBAA4D519AB3Q33520683-AC356C14-8B02-46C5-AE74-4FA9889871ADQ33729233-328F61BA-390C-4415-B9F5-E049700FF446Q33891067-20EEB858-A823-4D38-9355-09E4CE106A4BQ33949566-6D593BD1-4556-4451-87AF-798CD2257D17Q34016389-03AA7EC4-AFB8-4D15-A094-F2E425281E14Q34044002-58C39988-BB3C-4E25-94BA-CE4CE5D4E82DQ34218138-350B989F-DFBB-4372-B351-A399C6692751Q34267133-B5C70539-90AE-48F0-8D4C-D38078AC7012Q34269852-B12125E5-6C09-4FEE-8964-536F4F0E367EQ34278963-3B20C8B9-21DF-4A2F-B29F-58A5F288A538Q34321055-2B93CB66-F8CE-4FA7-A8F9-3740EB6C950DQ34382594-E6F0EC69-4C7E-47EA-BF63-FB3952E89199Q34400131-1FAF882A-8B88-45D8-9CBA-E20217A2BDC0Q34420756-731C3766-9914-4AD6-8A76-68B75796E0AEQ34482117-15A7F080-4228-4492-AD90-DF3DBB27118EQ34563213-506255FD-274A-457D-BAB2-F0693F101588Q34572118-7BBEEFF4-B089-472A-95DB-0927F3965CE8Q34572780-1FC15C18-35F2-4675-8A85-4D1C95551203Q34613459-AB7B55BD-EE40-4272-A7D9-69A6F3122AB7Q34632422-72D170CA-53D5-41AE-9C7B-940AEDAEA7E2Q34719679-231FDDE8-F9BD-4416-A200-C864F1157968Q34858094-47C2A485-5C1C-4C1C-BF29-96B5CBFEC6C0
P50
description
forsker
@nb
name
Christer Halldin
@ast
Christer Halldin
@da
Christer Halldin
@de
Christer Halldin
@en
Christer Halldin
@es
Christer Halldin
@fr
Christer Halldin
@nb
Christer Halldin
@nl
Christer Halldin
@nn
Christer Halldin
@sl
type
label
Christer Halldin
@ast
Christer Halldin
@da
Christer Halldin
@de
Christer Halldin
@en
Christer Halldin
@es
Christer Halldin
@fr
Christer Halldin
@nb
Christer Halldin
@nl
Christer Halldin
@nn
Christer Halldin
@sl
prefLabel
Christer Halldin
@ast
Christer Halldin
@da
Christer Halldin
@de
Christer Halldin
@en
Christer Halldin
@es
Christer Halldin
@fr
Christer Halldin
@nb
Christer Halldin
@nl
Christer Halldin
@nn
Christer Halldin
@sl
P106
P21
P214
892148997671459870009
P27
P31
P5463
Halldin_Christer
P7859
viaf-892148997671459870009